Active substance
Minocycline
- SFDA 6
- US FDA 42
- Health Canada 3
- US price lines 7
- NHS prices 1
- Safety 6
SFDA Saudi Arabia — SFDA human drug list
| Trade name | Strength | Form · route | Pack | Public price | Type | Company | Status |
|---|---|---|---|---|---|---|---|
| VULGA 105 mg XR film-coated tablet | 105 mg | Prolonged-release tablet · Oral use | 30 Blister | SAR 130.00 | Generic · Prescription | Jazeera Pharmaceutical Industries (JPI) | Valid |
| VULGA 55 mg XR film-coated tablet | 55 mg | Prolonged-release tablet · Oral use | 30 Blister | SAR 70.00 | Generic · Prescription | Jazeera Pharmaceutical Industries (JPI) | Valid |
| VULGA 65 mg XR film-coated tablet | 65 mg | Prolonged-release tablet · Oral use | 30 Blister | SAR 80.45 | Generic · Prescription | Jazeera Pharmaceutical Industries (JPI) | Valid |
| VULGA 80 mg XR film-coated tablet | 80 mg | Prolonged-release tablet · Oral use | 30 Blister | SAR 100.00 | Generic · Prescription | Jazeera Pharmaceutical Industries (JPI) | Valid |
| MINOCIN 100MG PELLET FILLED CAPS | 100 mg | Capsule · Oral use | 20 Blister | SAR 54.05 | NCE · Prescription | WYETH | Withdrawn by MAH · Not Marketed |
| MINOCIN 50MG PELLET FILLED CAPS | 50 mg | Capsule · Oral use | 30 Blister | SAR 42.25 | NCE · Prescription | WYETH | Withdrawn by MAH · Not Marketed |
Indications — CHI Daman Drug Formulary
BACTERIAL SKIN INFECTIONS - PURULENT SKIN AND SOFT TISSUE INFECTIONS (CUTANEOUS ABSCESSES, FURUNCLES, CARBUNCLES); MUCOSAL ULCERATION; OSTEOMYELITIS; PAPULOPUSTULAR ROSACEA
US FDA United States — FDA approvals (Drugs@FDA)
| Product | Strength | Form · route | Applicant | Status | First approved |
|---|---|---|---|---|---|
| MINOCIN | EQ 100MG BASE/VIAL | injectable · injection | REMPEX | Prescription | 26 Oct 1972 |
| MINOCIN | EQ 50MG BASE; EQ 100MG BASE | capsule · oral | BAUSCH | Prescription | 31 May 1990 |
| MINOCYCLINE HYDROCHLORIDE | EQ 100MG BASE; EQ 75MG BASE | capsule · oral | WATSON LABS | Prescription | 30 Dec 1991 |
| MINOCYCLINE HYDROCHLORIDE | EQ 50MG BASE | capsule · oral | WATSON LABS TEVA | Prescription | 30 Dec 1991 |
| MINOCYCLINE HYDROCHLORIDE | EQ 100MG BASE; EQ 75MG BASE | capsule · oral | ZYDUS | Prescription | 2 Mar 1992 |
| MINOCYCLINE HYDROCHLORIDE | EQ 50MG BASE | capsule · oral | ZYDUS | Prescription | 2 Mar 1992 |
| MINOCYCLINE HYDROCHLORIDE | EQ 50MG BASE; EQ 100MG BASE; EQ 75MG BASE | capsule · oral | IMPAX LABS | Prescription | 23 Mar 1999 |
| MINOCYCLINE HYDROCHLORIDE | EQ 50MG BASE; EQ 75MG BASE; EQ 100MG BASE | capsule · oral | TORRENT | Prescription | 30 Nov 2000 |
| ARESTIN | EQ 1MG BASE | powder, extended release · dental | ORAPHARMA | Prescription | 16 Feb 2001 |
| MINOCYCLINE HYDROCHLORIDE | EQ 50MG BASE; EQ 75MG BASE; EQ 100MG BASE | tablet · oral | STRIDES PHARMA INTL | Prescription | 16 Apr 2003 |
| MINOCYCLINE HYDROCHLORIDE | EQ 50MG BASE; EQ 75MG BASE; EQ 100MG BASE | tablet · oral | TORRENT | Prescription | 6 Jan 2004 |
| MINOCYCLINE HYDROCHLORIDE | EQ 50MG BASE; EQ 75MG BASE; EQ 100MG BASE | tablet · oral | CHARTWELL RX | Prescription | 26 Dec 2007 |
| MINOCYCLINE HYDROCHLORIDE | EQ 50MG BASE; EQ 75MG BASE; EQ 100MG BASE | capsule · oral | AUROBINDO PHARMA | Prescription | 11 Mar 2008 |
| MINOCYCLINE HYDROCHLORIDE | EQ 45MG BASE; EQ 90MG BASE; EQ 135MG BASE | tablet, extended release · oral | SANDOZ | Prescription | 13 Aug 2009 |
| MINOCYCLINE HYDROCHLORIDE | EQ 45MG BASE; EQ 55MG BASE; EQ 90MG BASE; EQ 135MG BASE | tablet, extended release · oral | LUPIN | Prescription | 30 Nov 2011 |
| MINOCYCLINE HYDROCHLORIDE | EQ 45MG BASE; EQ 65MG BASE; EQ 90MG BASE; EQ 115MG BASE; EQ 135MG BASE; EQ 80MG BASE; EQ 105MG BASE; EQ 55MG BASE | tablet, extended release · oral | AUROBINDO PHARMA LTD | Prescription | 19 Nov 2012 |
| MINOCYCLINE HYDROCHLORIDE | EQ 45MG BASE; EQ 80MG BASE; EQ 90MG BASE; EQ 105MG BASE; EQ 135MG BASE; EQ 65MG BASE; EQ 115MG BASE; EQ 55MG BASE | tablet, extended release · oral | ALKEM LABS LTD | Prescription | 28 Sep 2016 |
| AMZEEQ | EQ 4% BASE | aerosol, foam · topical | JOURNEY | Prescription | 18 Oct 2019 |
| MINOCYCLINE HYDROCHLORIDE | EQ 50MG BASE; EQ 75MG BASE; EQ 100MG BASE | tablet · oral | AUROBINDO PHARMA LTD | Prescription | 1 May 2020 |
| ZILXI | EQ 1.5% BASE | aerosol, foam · topical | JOURNEY | Prescription | 28 May 2020 |
| MINOCYCLINE HYDROCHLORIDE | EQ 50MG BASE; EQ 75MG BASE; EQ 100MG BASE | tablet · oral | REGCON HOLDINGS | Prescription | 27 May 2022 |
| EMROSI | EQ 40MG BASE | capsule, extended release · oral | JOURNEY | Prescription | 1 Nov 2024 |
| MINOCYCLINE HYDROCHLORIDE | EQ 100MG BASE/VIAL | injectable · injection | NEXUS | Prescription | |
| MINOCIN | EQ 100MG BASE; EQ 50MG BASE | capsule · oral | TRIAX PHARMS | Discontinued | 30 Jun 1971 |
| MINOCIN | EQ 50MG BASE/5ML | suspension · oral | BAUSCH | Discontinued | 26 Oct 1972 |
17 more — full table
Canada Canada — marketed products (Health Canada)
| Brand | DIN | Strength | Form · route | Company |
|---|---|---|---|---|
| ARESTIN MICROSPHERES | 02278219 | 1 MG / 4 MG | POWDER (EXTENDED-RELEASE) · SUBGINGIVAL | ORA PHARMA INC. |
| MINOCYCLINE | 02084090 | 50 MG | CAPSULE · ORAL | AA PHARMA INC |
| MINOCYCLINE | 02084104 | 100 MG | CAPSULE · ORAL | AA PHARMA INC |
Prices — United States and England
| Source | Product as listed | Price | Unit / pack | Date |
|---|---|---|---|---|
| US NADAC | MINOCYCLINE 100 MG CAPSULE | $0.34252 | per EA | 23 Sep 2026 |
| US NADAC | MINOCYCLINE 50 MG CAPSULE | $0.18012 | per EA | 23 Sep 2026 |
| US NADAC | MINOCYCLINE 75 MG CAPSULE | $0.39676 | per EA | 23 Sep 2026 |
| US NADAC | MINOCYCLINE ER 90 MG TABLET | $3.03047 | per EA | 19 Nov 2025 |
| US NADAC | MINOCYCLINE HCL 100 MG TABLET | $0.70414 | per EA | 23 Sep 2026 |
| US NADAC | MINOCYCLINE HCL 50 MG TABLET | $0.34351 | per EA | 23 Sep 2026 |
| US NADAC | MINOCYCLINE HCL 75 MG TABLET | $0.30184 | per EA | 5 Aug 2026 |
| NHS Drug Tariff | Minocycline 100mg modified-release capsules | £20.08 | 56 capsule | 1 Oct 2026 |
NADAC: average price US retail pharmacies pay to buy the medicine. NHS Drug Tariff Part VIIIA: basic price reimbursed to pharmacies in England and Wales.
Safety signals and safety-related labeling changes
- US FDA 29 Jan 2026 XIMINO — safety-related labeling change
Labeling sections changed: Contraindications; Warnings and Precautions; Adverse Reactions; Drug Interactions; Use in Specific Populations; Patient Counseling Information / Patient Information / Medication Guide - US FDA 1 Apr 2025 SOLODYN — safety-related labeling change
Labeling sections changed: Contraindications; Warnings and Precautions; Adverse Reactions; Drug Interactions; Use in Specific Populations; Patient Counseling Information / Patient Information / Medication Guide - US FDA 31 Mar 2025 MINOCIN — safety-related labeling change
Labeling sections changed: Warnings and Precautions; Adverse Reactions - US FDA 31 Mar 2025 MINOCIN — safety-related labeling change
Labeling sections changed: Warnings and Precautions; Adverse Reactions - US FDA 31 Mar 2025 MINOCIN — safety-related labeling change
Labeling sections changed: Warnings and Precautions - US FDA 24 May 2024 ARESTIN — safety-related labeling change
Labeling sections changed: Warnings and Precautions; Adverse Reactions
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.